Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ratiopharm
The strategy for both funds is to back companies with a preclinical drug candidate that can be advanced through clinical proof-of-concept with a mid-sized series A round.
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.
Private Company Edition: Dyno’s first VC round will enable more deals for its novel AAV platform; Eikon pioneers new drug discovery technology. Also, Treeline’s early funding revealed at $211.7m; Capsida raised $140m from a VC round, AbbVie deal; and Affinia closed a $110m series B round.
Pfizer will develop the novel antifungal fosmanogepix. The big pharma has made several other recent anti-infective deals, including when it expanded its BioNTech vaccine alliance to include COVID-19.
- Other Names / Subsidiaries
- BioGeneriX AG
- Neose Technologies, Inc.